HTA Principles Survey Questionnaire
|
|
- Alisha Wilkins
- 5 years ago
- Views:
Transcription
1 I. Introduction This survey aims to inform health care decision makers in their rational and efficacious applications of health technology assessment (HTA) in Asia, while adhering to key established benchmarks. These benchmarks may be referred to as the 15 key principles of HTA [1, 2, 3]. The principles strive to outline the best practices for HTA application, following the organizational structure, methodology, process of implementation, and the use of information in health care decision making. Through this survey, it is hoped that data may be captured to accurately reflect the current HTA situation across Asia and ultimately generate evidence for better-informed health care decisions. II. Questionnaire Instructions 1. This questionnaire is designed to evaluate the HTA system at the level of your country/jurisdiction. HTA processes may include (1) HTA organization (such as the department who manage the health insurance coverage decision process within the Ministry of Health or Health Insurance Scheme, or an independent organization assigned by the government; (2) HTA appraisal committee; or (3) agencies who conduct HTA assessment and generate the report. 2. There are 15 key principles of HTA, with corresponding questions. For each principle 1-15, first indicate the relevance (usefulness) of the principle to your particular country s context, rating from Extremely relevant to Not Relevant. 3. After rating the relevancy, please include any specific comments pertaining to the principle s relevancy in your country. 4. For each principle s corresponding question, mark the appropriate box (yes, no or unsure) with a check mark. 5. Please send the completed survey (saved PDF) to asiaconsortium@ispor.org.
2 III. Responder Information HTA Principles Survey Questionnaire 1. Your Country or Region: 2. Your Organization name: 3. How would you classify your organization? a. Central/Federal Government b. Local/Provincial/State Government c. Professional (e.g. medical-related society) d. Pharmaceutical/Medical Device Industry e. Academic/Not for profit Research Institution f. Hospital g. Private insurer/managed care h. Other (Please state in the text field provided) 4. Does your organization do any of the following: a. Coordinate HTA activities (in the country concerned) b. Make reimbursement decisions, or issue guidance based on HTAs c. Assess HTAs (e.g. Industry submissions) d. Undertake HTAs e. None of the above 5. Your Name (optional) 6. Your Contact Information (optional) Phone: Address: 2
3 IV. Questionnaire Structure of HTA 1. The goal and scope of the HTA should be explicit and relevant to its use. Please indicate the relevance of Principle # 1 to your country s HTA processes t Relevant 1.1 Is the remit of the HTA organization clearly defined? 1.2 Is a scoping document drawn up prior to an HTA, containing information on the specific decision problem to be addressed, the relevant patient populations to be considered, the intervention of interest, the relevant alternatives (comparators), and the outcomes (PICOs) to be assessed? 2. HTA should be an unbiased and transparent exercise. Please indicate the relevance of Principle # 2 to your country s HTA processes t Relevant 2.1 Is the HTA assessment agency independent of the body making the reimbursement or coverage decision? 3
4 2.2 Are the recommendations of the HTA organization made by an independent expert advisory committee? 2.3 Are any conflicts of interest of committee members documented and made public? 2.4 Are the meetings of the committee held in public? 2.5 Is the supporting information and the basis of the recommendations made publicly available? 2.6 Does the organization normally commission outside groups to undertake the health technology assessment? 2.7 Are the reports produced subjected to independent peer-review prior to final determination? 2.8 Are the draft conclusions subject to review by stakeholders and the public, with rationale underlying final determinations of contentious issues? 4
5 3. HTA should include all relevant technologies. HTA Principles Survey Questionnaire Please indicate the relevance of Principle # 3 to your country s HTA processes t Relevant 3.1 Are all types of technologies (e.g. drugs, devices, diagnostics, procedures, behavioral modification) considered? 3.2 Within each category, are both new and existing technologies considered? 3.3 In assessments of new technologies, are all relevant alternatives considered? 4. A clear system for setting priorities for HTA should exist. Please indicate the relevance of Principle # 4 to your country s HTA processes t Relevant 5
6 4.1 Does a formal system for prioritizing and selecting topics exist? 4.2 Is the priority-setting approach clear and transparent? Methods of HTA 5. HTA should incorporate appropriate methods for assessing costs and benefits. Please indicate the relevance of Principle # 5 to your country s HTA processes t Relevant 5.1 Does the HTA organization consider costs as well as benefits and harms? 5.2 Does the HTA organization have published methods guidelines for assessing the benefits, harms and costs of health technologies? 6
7 5.3 Is a full systematic review of clinical evidence required as a basis for economic modeling? 5.4 Does the team undertaking HTA assessments on behalf of the organization include individuals with skills in epidemiology/biostatistics, health services research and economics? 6. HTAs should consider a wide range of evidence and outcomes. Please indicate the relevance of Principle # 6 to your country s HTA processes t Relevant 6.1 Does the relevant clinical evidence include observational and non-randomized studies, as well as RCTs? 6.2 Does the HTA consider impacts on quality of life and other patient-reported outcomes, as well as clinical events? 6.3 Does the HTA consider relevant sub-groups of the patient population (e.g. by baseline risk)? 7
8 7. A full societal perspective should be considered when undertaking HTAs. Please indicate the relevance of Principle # 7 to your country s assessment process t Relevant 7.1 Does the HTA only consider the impact on a specific budget, for example for drugs? 7.2. Does the HTA consider all health care costs? 7.3. Can other costs be included as extra information? 7.4. Are productivity gains and losses (i.e., indirect costs and benefits) considered when relevant? 7.5. Are costs for informal care included when relevant? 8
9 7.6. Are costs in added years of life included in the cost-effectiveness ratio? 8. HTAs should explicitly characterize uncertainty surrounding estimates. Please indicate the relevance of Principle # 8 to your country s assessment process t Relevant 8.1. Does the HTA include a sensitivity analysis? 8.2. Are confidence intervals presented for key estimates? 8.3. Have the key deficiencies in available data been identified and discussed? 8.4. Is an agenda for key future research proposed? 9
10 9. HTAs should consider and address issues of generalizability and transferability. Please indicate the relevance of Principle # 9 to your country s HTA processes t Relevant 9.1. Does the HTA organization have methods guidance for dealing with transferability issues when using data or analyses from other jurisdictions? 9.2. Does the HTA organization consider the generalizability of the results of its studies to other patient populations, health care delivery systems or practice settings that are relevant for its jurisdiction? Processes for Conducting HTA 10. Those conducting HTAs should actively engage all key stakeholder groups. Please indicate the relevance of Principle # 10 to your country s HTA processes t Relevant 10
11 10.1. Is the HTA organization formally required to engage stakeholders in its activities? Does the HTA organization involve stakeholders in the scoping of HTAs? Does the HTA organization have a mechanism for identifying the relevant stakeholders? Does the HTA organization encourage or require submissions of evidence from stakeholders? Does the HTA organization allow stakeholders to comment on HTA assessment reports at the draft stage? Does the HTA organization allow stakeholders to appeal against recommendations/ decisions? 11
12 10.7. Do the HTA organization s appraisal committees include stakeholder representation (e.g. patient groups, technology manufacturers, clinical specialists)? 11. Those undertaking HTAs should actively seek all available data Please indicate the relevance of Principle # 11 to your country s HTA processes t Relevant Does the systematic review of clinical evidence include the gray literature and unpublished data? Does the HTA organization have processes for handling confidential data from manufacturers? 12. The implementation of HTA findings needs to be monitored. Please indicate the relevance of Principle # 12 to your country s HTA processes t Relevant 12
13 12.1. Does the HTA organization develop an implementation plan for its HTAs? Does the HTA organization monitor the impact of its recommendations? Use of HTA in Decision Making 13. HTA should be timely. Please indicate the relevance of Principle # 13 to your country s HTA processes t Relevant Does the HTA organization have a defined time period for conducting HTAs/producing recommendations? Does the HTA organization adhere to the agreed timelines? Does the organization have a mechanism to update its HTAs/recommendations within a given time period? 13
14 14. HTA findings need to be communicated appropriately to different decision makers. Please indicate the relevance of Principle # 14 to your country s HTA processes t Relevant Does the HTA organization develop a communications plan for its recommendations and decisions? Are separate versions of reports produced for different audiences (e.g. health professionals, decision makers, general public)? Is the effectiveness of communication monitored and evaluated? 15. The link between health technology assessment and decision-making processes needs to be transparent and clearly defined. Please indicate the relevance of Principle # 15 to your country s HTA processes t Relevant 14
15 15.1. Does the organization distinguish between the scientific assessment of the evidence and the appraisal decision? Does the organization have an explicit decision rule for acceptance/non-acceptance of health technologies? Does the organization have a transparent approach for weighing various considerations (e.g. comparative effectiveness, cost-effectiveness, budget impact, equity)? Does the organization recommend, or operate, conditional reimbursement/coverage-with-evidencedevelopment schemes? Does the organization distinguish between identifiable sub-groups of the patient population when making decisions? 15
16 V. References This survey is compiled by Dr. Yen-Huei (Tony) Tarn on behalf of HTAnetAsia of ISPOR Asia Consortium based on the following articles with the permissions from the authors: [1] Drummond M, Schwartz JS, Jonsson B, et al. Key principles for the improved conduct of health technology assessments for resource allocation decisions. International Journal of Technology Assessment in Health Care 2008; 24: [2] Neumann P, Drummond M, Jonsson B, et al. Are Key Principles for improved health technology assessment supported and used by health technology assessment organizations? International Journal of Technology Assessment in Health Care 2010; 26: [3] Drummond M, Neumann P, Jonsson B, et al. Can We Reliably Benchmark Health Technology Assessment organizations? International Journal of Technology Assessment in Health Care 2012; 28:2,
OPTIMAL USE PROGRAM DRUG Therapeutic Review Framework and Process
OPTIMAL USE PROGRAM DRUG Therapeutic Review Framework and Process Version: 3.0 Publication Date: June 27, 2018 Report Length: 16 Pages Revision History From time to time, CADTH may amend the therapeutic
More informationEnvironmental Scan Process
CADTH Environmental Scan Process May 2015 Version 1.0 REVISION HISTORY Periodically, this document will be revised as part of ongoing process improvement activities. The following version control table,
More informationHTA methodology at HIQA. Conor Teljeur
HTA methodology at HIQA Conor Teljeur What is HTA? Health technology assessment (HTA) is a multidisciplinary process that summarises information about the medical, social, economic and ethical issues related
More informationHotel Lutécia. Av. Frei Miguel Contreiras nº 52, , Lisbon, Portugal June 2016
Hotel Lutécia Av. Frei Miguel Contreiras nº 52, 1749-086, Lisbon, Portugal 26-29 June 2016 This three and a half day training program brings together leading experts in HTA to teach good practices in the
More informationPage 1 of 8. Better informed health care through better clinical guidelines
Introduction The Guidelines International Network (G-I-N) Australian and New Zealand Regional Community was established to provide a forum to support the collaboration of organisations and individuals
More informationElected Official and Governing Board Self-Evaluation Tool
Elected Official and Governing Board Self-Evaluation Tool Developed May 2015 Frederick Steinmann, DPPD Assistant Research Professor/Leadership and Economic Development Specialist The College of Business
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health and Social Care Directorate. Indicator Process Guide. Published December 2017
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health and Social Care Directorate Indicator Process Guide Published December 2017 Please note that this is an interim factual update to the NICE Indicator
More informationRevolution, Evolution, or Status Quo? Guidelines for Efficiency Measurement in Health Care
Revolution, Evolution, or Status Quo? Guidelines for Efficiency Measurement in Health Care Professor Bruce Hollingsworth Director, Monash University E-mail: bruce.hollingsworth@monash.edu Efficiency Measurement
More informationNICE Guidelines: A Methodological Basis for Decision Making. Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham
NICE Guidelines: A Methodological Basis for Decision Making Rod Taylor MSc, PhD Dept of Public Health & Epidemiology University of Birmingham Pre Meeting Symposium - ISPOR Annual Conference Washington
More informationMinimum Elements and Practice Standards for Health Impact Assessment. North American HIA Practice Standards Working Group
Minimum Elements and Practice Standards for Health Impact Assessment Version 2 November 2010 Authorship and Acknowledgements This document represents a revision of version one of Practice Standards for
More informationSingle Drug Technology Assessment Processes Across Health Technology Assessment Organizations
CADTH ENVIRONMENTAL SCAN Single Drug Technology Assessment Processes Across Health Technology Assessment Organizations Product Line: Environmental Scan Version: 1.0 Issue Number: 55 Publication Date: November
More informationHTA of Medical Devices in Asia Pacific
HTA of Medical Devices in Asia Pacific Devarshi Bhattacharyya MPH, MSc Health Economics Assistant Director Kalam Institute of Health Technology, India Agenda Background Pharmaceuticals vs Medical Devices
More informationIndirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee
Indirect Comparisons in Economic Evaluations: Experience from the Common Drug Review Julie Blouin, Karen M Lee 2009 CADTH Symposium April 6, 2009, Ottawa, ON Presentation Outline Background on indirect
More informationA Public Interest Framework for the Accountancy Profession
International Federation of Accountants Exposure Draft November 2010 Comments requested by March 25, 2011 IFAC Policy Position Paper #4 A Public Interest Framework for the Accountancy Profession REQUEST
More informationHTA and market access issues for a complex intervention
5th HTA network meeting, Paris 29th October 2015 HTA and market access issues for a complex intervention Marianne Klemp, Research Director, Norwegian Knowledge Centre for the Health Services, NOKC Example
More informationEvaluation & Decision Guides
SURGERY STRATEGIC CLINICAL NETWORK EVIDENCE DECISION SUPPORT PROGRAM Evaluation & Decision Guides 2014 Revision (v3) New ideas & Improvements Department of Surgery Evidence Decision Support Program Resource
More informationECONOMIC EVALUATION AND HEALTH TECHNOLOGY ASSESSMENT IN EUROPE AND USA A Comparative Analysis
Coordinator: Università Bocconi CERGAS Via Röntgen 1 20136 Milan (Italy) www.medtechta.eu ECONOMIC EVALUATION AND HEALTH TECHNOLOGY ASSESSMENT IN EUROPE AND USA A Comparative Analysis Executive Summary
More informationStakeholder Involvement Policy Standard Operating Procedures
Stakeholder Involvement Policy Standard Operating Procedures EUnetHTA Joint Action 2010-2012 Reference: EUnetHTA Joint Action 2010-2012, Stakeholder Involvement SOP, October 2010 1 Stakeholder involvement
More informationMyeloma UK Policy Working with the Pharmaceutical Industry
Policy Working with the Pharmaceutical Industry Background The relationship between patient organisations and the pharmaceutical industry has come under increasing scrutiny in recent times, with the media
More informationCochrane Consumer and Communication Group (CCCG) review updating guidance and policy: for authors
Cochrane Consumer and Communication Group (CCCG) review updating guidance and policy: for authors This document contains the 2017 version of the CCCG updating guidance and policy. In 2016, after several
More informationNICE methods of technology appraisal
NICE methods of technology appraisal Zoe Garrett Senior Technical Adviser, Centre for Health Technology Evaluation National Institute for Health and Care Excellence (NICE) Contents Function of NICE Work
More informationRegulatory system strengthening
SIXTY-SEVENTH WORLD HEALTH ASSEMBLY A67/32 Provisional agenda item 15.6 14 March 2014 Regulatory system strengthening Report by the Secretariat 1. The Executive Board at its 134th session noted an earlier
More informationSafety Perception / Cultural Surveys
Safety Perception / Cultural Surveys believes in incorporating safety, health, environmental and system management principles that address total integration, thus ensuring continuous improvement, equal
More informationPolicies and Procedures Procedures for Processing Documents
Policies and Procedures Procedures for Processing Documents Date: March Due for review: March 2021 Page2 General foreword This document supersedes any previous document covering the policies and procedures
More informationChairman of Hillingdon HealthWatch. Recruitment Pack
Chairman of Hillingdon HealthWatch Recruitment Pack HealthWatch Chairman needed Advertisement A new body to oversee health and social care services is being set up to help residents and communities influence
More informationCADTH COMMON DRUG REVIEW. Procedure for the CADTH Common Drug Review
CADTH COMMON DRUG REVIEW Procedure for the CADTH Common Drug Review AUGUST 2014 RECORD OF UPDATES TO THE PROCEDURE FOR THE CADTH COMMON DRUG REVIEW Update Original June 2003 1 January 2005 2 July 2005
More informationMaking priority setting and resource allocation decisions from principles to practices
Making priority setting and resource allocation decisions from principles to practices Craig Mitton and Howard Waldner University of British Columbia New Caledonia Solutions Prioritize Consulting craig.mitton@ubc.ca
More informationHealth Planning and Health Technology Overview
Health Planning and Health Technology Overview Dr Kerrin Begg With acknowledgement to Mladen Poluta Director: HTM Programme University of Cape Town / Groote Schuur Hospital & MRC/WHO Collaborating Centre
More information2014 CLINICAL POLICY UNIT. Dr Vesna Kupresan
2014 CLINICAL POLICY UNIT Dr Vesna Kupresan Healthcare Industry Challenges Medical inflation Cost drivers Aging population Increased utilization of healthcare Growing chronic disease burden Rapid evolution
More informationTerms of Reference IPC Compliance Review Policy and Process
Terms of Reference IPC Compliance Review Policy and Process Endorsed December 5, 2014 BACKGROUND AND RATIONALE The Integrated Food Security Phase Classification (IPC) is a global, multi-partner innovative
More informationCADTH s Proposed Process for the Assessment of Companion Diagnostics
CADTH s Proposed Process for the Assessment of Companion Diagnostics 1. Preamble Companion diagnostics identify subgroups of patients for whom select drugs are likely to be most effective and safe. Based
More informationEUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL PUBLIC CONSULTATION
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE-GENERAL Healthcare systems Health systems and products PUBLIC CONSULTATION Brussels, 31 July 2012 on the modalities of stakeholder consultation in the
More informationA Guide to the Gender-inclusive Job Evaluation Standard NZS 8007:2006
A Guide to the Gender-inclusive Job Evaluation Standard NZS 8007:2006 A Guide to the Gender-inclusive Job Evaluation Standard NZS 8007:2006 Disclaimer: The Ministry of Business, Innovation & Emplyment
More informationGuide to the processes of technology appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guide to the processes of technology appraisal January 2018 Acknowledgements NICE is very grateful to everyone who contributed to the development of this
More informationConvergence and difference in HTA approaches in UK, Germany and France: reflections on recent and proposed changes
Convergence and difference in HTA approaches in UK, Germany and France: reflections on recent and proposed changes Professor Ron Akehurst School of Health and Related Research Content of Talk During this
More informationA Quality Assurance Framework for Knowledge Services Supporting NHSScotland
Knowledge Services B. Resources A1. Analysis Staff E. Enabling A3.1 Monitoring Leadership A3. Measurable impact on health service Innovation and Planning C. User Support A Quality Assurance Framework for
More informationEUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY
EUROPEAN COMMISSION DIRECTORATE-GENERAL FOR HEALTH AND FOOD SAFETY Health systems, medical products and innovation Medicines: policy, authorisation and monitoring STAMP 4/24 Record STAMP Commission Expert
More informationOrganizing Framework for a Functional National HIV Monitoring & Evaluation System
Regional Training on Strategic and Operational Planning in HIV & AIDS Organizing Framework for a Functional National HIV Monitoring & Evaluation System Final Draft for submission to the HIV Monitoring
More informationVALUE ADDED MEDICINES. Prof. Mondher Toumi, Professor of Public Health, Aix-Marseille University
VALUE ADDED MEDICINES Prof. Mondher Toumi, Professor of Public Health, Aix-Marseille University What Are Value Added Medicines? Value added medicines are defined as medicines based on known molecules that
More informationPublications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity
Publications for payors: what evidence do they really need? Ian Pickles, Strategy Consultant, Complete Clarity OBJECTIVES FOR THE SESSION To be able to build payer evidence requirements into publication
More informationA FRAMEWORK FOR AUDIT QUALITY. KEY ELEMENTS THAT CREATE AN ENVIRONMENT FOR AUDIT QUALITY February 2014
A FRAMEWORK FOR AUDIT QUALITY KEY ELEMENTS THAT CREATE AN ENVIRONMENT FOR AUDIT QUALITY February 2014 This document was developed and approved by the International Auditing and Assurance Standards Board
More informationStakeholder Consultation: Supplemental Process for Complex/Specialized Drugs Background Document
In 2014, the Provincial/Territorial (PT) Health Ministers established the Expensive Drugs for Rare Diseases Working Group (EDRD WG). The working group s mandate is to explore the management of rare disease
More informationManagement Job Evaluation Management Job Evaluation Plan (MJEP)
Management Job Evaluation Management Job Evaluation Plan (MJEP) 1 Job Evaluation What is Job Evaluation? Job evaluation is a systematic review and analysis of job responsibilities, relationships and requirements
More informationHealth Technology Assessment and Pragmatic Controlled Trials
Health Technology Assessment and Pragmatic Controlled Trials 6 th Annual Meeting of Health Technology Assessment International Singapore june 2009 Associate Professor Eva Draborg Institute of Public Health
More informationDECOMMISSIONING AND DISINVESTMENT STRATEGY CCG: CS01
NHS Milton Keynes Clinical Commissioning Group DECOMMISSIONING AND DISINVESTMENT STRATEGY CCG: CS01 Version: 0.1 Ratified by: To be ratified by Board Date ratified: 26.07.16 Name of originator / author:
More informationCanadian Task Force on Preventive Health Care Procedure Manual
Canadian Task Force on Preventive Health Care Procedure Manual October 2011 Page 1 Table of Contents Section 1: Overview of structure and processes... 7 1.1 Function... 7 1.2 Governance... 7 1.3 Overview
More informationThis template is to be used by companies willing to submit an overview of relevant
Briefing book template for pharmaceuticals to support a multi-hta Early Dialogue (ED) December 13 th, 2013 This template is to be used by companies willing to submit an overview of relevant information
More informationCode of Corporate Governance
Code of Corporate Governance 1 FOREWORD From the Chairman of the General Purposes Committee I am pleased to endorse this Code of Corporate Governance, which sets out the commitment of Cambridgeshire County
More informationCitation for the original published paper (version of record):
http://www.diva-portal.org Postprint This is the accepted version of a paper published in Patient. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal
More informationILO Training Package on Development of a National Programme of Occupational Safety and Health
0 International Labour Of fice Geneva ILO Training Package on Development of a National Programme of Occupational Safety and Health 0 ILO Training Package on Development of a National Programme of Occupational
More informationConsultation questions
Consultation questions The IIRC welcomes comments on all aspects of the Draft International Framework (Draft Framework) from all stakeholders, whether to express agreement or to recommend changes.
More informationGuidelines for the Economic Evaluation of Health Technologies in Ireland
Guidelines for the Economic Evaluation of Health Technologies in Ireland 2018 1 About the The (HIQA) is an independent authority established to drive high-quality and safe care for people using our health
More informationGood Practices for Synthesizing and Using Evidence in Health Care Decision Making?
Good Practices for Synthesizing and Using Evidence in Health Care Decision Making? An ISPOR Workshop presented by the ISPOR HTA Council Working Group ISPOR 22 nd Annual International Meeting Boston, MA,
More informationISO INTERNATIONAL STANDARD. Risk management Principles and guidelines. Management du risque Principes et lignes directrices
INTERNATIONAL STANDARD ISO 31000 First edition 2009-11-15 Risk management Principles and guidelines Management du risque Principes et lignes directrices http://mahdi.hashemitabar.com Reference number ISO
More informationJob description and person specification
Job description and person specification Position Job title Knowledge Management Facilitator Directorate Operations and Information Pay band AFC Band 8a Responsible to NHS RightCare Knowledge Management
More informationScottish Medicines Consortium
Scottish Medicines Consortium Guidance to Manufacturers for Completion of New Product Assessment Form (NPAF) (Revised June 2007) Part A: General guidance for completion of the NPAF Part B: Guidance for
More informationAssessing trends in SMC Advice Decisions (October September 2015)
Consulting Report November 2015 Assessing trends in SMC Advice Decisions (October 2009- September 2015) This report was initiated and funded by Pfizer Ltd For further information please contact: Phill
More informationIAESB Strategy and Work Plan
International Accounting Education Standards Board April 2010 IAESB 2010 2012 Strategy and Work Plan International Accounting Education Standards Board International Federation of Accountants 545 Fifth
More informationEVALUATING PERFORMANCE: Evolving Approaches To Evaluating Performance Measurement Programs
EVALUATING PERFORMANCE: Evolving Approaches To Evaluating Performance Measurement Programs Kevin Park, MD Principal and Medical Director Attest Health Care Advisors, LLC Joann Richards, RN, PhD Vice President
More informationA Guide to Clinical Coding Audit Best Practice Version 8.0
A Guide to Clinical Coding Audit Best Practice Version 8.0 Copyright 2017 Health and Social Care Information Centre Page 1 of 17 The Health and Social Care Information Centre is a non-departmental body
More informationCI-GEF PROJECT AGENCY MONITORING AND EVALUATION POLICY FOR GEF-FUNDED PROJECTS
CI-GEF PROJECT AGENCY MONITORING AND EVALUATION POLICY FOR GEF-FUNDED PROJECTS Version 02 March 2016 1 DOCUMENT LOG AND CHANGE RECORD Version Date Changes/Comments Author(s) 01 Oct 2013 Version submitted
More informationPositive Behavior Support Facilitator Portfolio Expedited Process Application Contents of Portfolio Packet
Positive Behavior Support Facilitator Portfolio Expedited Process Application Contents of Portfolio Packet Cover Sheet Summary of Requirements Checklist of Portfolio Contents Résumé or Abbreviated Vitae
More informationVolunteer Services Policy
Volunteer Services Policy Version Number 4 Version Date 1 February 2014 Policy Owner Head of Operations Author Volunteer Services Co-ordinator Last Reviewed November 2013 Staff/Groups Consulted Head of
More informationGEROS Evaluation Quality Assurance Tool Version
GEROS Evaluation Quality Assurance Tool Version 2016.4 Title of the Evaluation Report Report sequence number Reviewers: complete all cells highlighted in Yellow Support to community sanitation in eastern
More informationOn-site Visit of LBI-HTA Oct 18th 2011
On-site Visit of LBI-HTA Oct 18th 2011 Visit Report Expert-visitors: Dr. Bert Boer, CVZ/ College voor zorgverzekeringen, NL Director CVZ Dr. Raf Mertens, KCE/ Kenniscentrum voor de Gezondheidszorg, BE
More informationRe: Docket No. 2006D-0347, Federal Register: July 26, 2007 (Volume 72, Pages )
1201 Maryland Avenue SW, Ste. 900 Washington, DC 20024 August 27, 2007 BY ELECTRONIC DELIVERY Division of Dockets Management (HFA-305) Food and Drug Administration 56350 Fishers Lane Room 1061 Rockville,
More informationGuidance on conducting consultations in the HRA Internal HRA guidance only
Guidance on conducting consultations in the HRA Internal HRA guidance only Author: Amanda Hunn Date of Release: 19 th February 2015 Version No. & Status: v.1.0 Final Approved by: EMT Supersedes Version:
More informationAccess Viewpoint FDA DRAFT GUIDANCE FOR PAYER COMMUNICATIONS: INSIGHTS AND IMPLICATIONS
Access Viewpoint FDA DRAFT GUIDANCE FOR PAYER COMMUNICATIONS: INSIGHTS AND IMPLICATIONS INTRODUCTION In January 2017, the FDA released draft guidance* Drug and Device Manufacturer Communications with Payors,
More informationBipartisan Policy Center, Top Medical Innovation Priorities
Bipartisan Policy Center, Top Medical Priorities FDA: Advancing Medical is a Bipartisan Policy Center initiative led by former Senator Bill Frist, MD, former Congressman Bart Gordon, and BPC Health Initiative
More informationMedical Product Communications That Are Consistent With the FDA-Required Labeling Questions and Answers Guidance for Industry
Medical Product Communications That Are Consistent With the FDA-Required Labeling Questions and Answers Guidance for Industry Elizabeth Pepinsky Health Science Policy Analyst Office of Prescription Drug
More informationHEALTH TECHNOLOGY ASSESSMENT GUIDELINES
HEALTH TECHNOLOGY ASSESSMENT GUIDELINES DRUG SUBMISSION GUIDELINES FOR NEW PRODUCTS, NEW INDICATIONS, AND NEW FORMULATIONS The WellPoint Outcomes Based Formulary SM WellPointNextRx Updated September 2008
More informationDeveloping Drugs for Rare Diseases: Patient Advocacy s Perspective. Kristina Bowyer Executive Director, Patient Advocacy
Developing Drugs for Rare Diseases: Patient Advocacy s Perspective Kristina Bowyer Executive Director, Patient Advocacy February 5, 2018 An Advocacy Perspective Why develop drugs for Rare Disease? What
More informationSubmission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016)
11 January 2018 Submission of comments on 'Reflection paper on the use of extrapolation in the development of medicines for paediatrics' (EMA/199678/2016) Comments from: Name of organisation or individual
More informationPharmaceutical Sector Governance in the Middle East and North Africa Region A Regional Review by the World Bank
Pharmaceutical Sector Governance in the Middle East and North Africa Region A Regional Review by the World Bank Presented at the Workshop on Governance of Pharmaceuticals in MENA Amman, Jordan June 6,
More information3-Year System Business Plan ( ) Companion Document
SC7 Meeting Agenda item 7 Issued: 31 October 2018 3-Year System Business Plan (2019-2021) Companion Document 2019-2021 Program Performance Management Standards Business Plan: Action Purpose: Action Requested:
More informationQuality Management in the Internal Audit Activity
German Institute of Internal Auditors (DIIR) DIIR Audit Standard No. 3 Quality Management in the Internal Audit Activity Published in August 2002 and amended in September 2015 (Version 1.1), Frankfurt
More informationMapping of Health Technology Assessment in Selected Countries
International Journal of Technology Assessment in Health Care, 29:4 (2013), 424 434. c Cambridge University Press 2013 doi:10.1017/s0266462313000469 Mapping of Health Technology Assessment in Selected
More informationRequirements Analysis and Design Definition. Chapter Study Group Learning Materials
Requirements Analysis and Design Definition Chapter Study Group Learning Materials 2015, International Institute of Business Analysis (IIBA ). Permission is granted to IIBA Chapters to use and modify this
More informationCost-effectiveness and cost-utility analysis accompanying Cancer Clinical trials. NCIC CTG New Investigators Workshop
Cost-effectiveness and cost-utility analysis accompanying Cancer Clinical trials NCIC CTG New Investigators Workshop Keyue Ding, PhD. NCIC Clinical Trials Group Dept. of Public Health Sciences Queen s
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Medical Technologies Evaluation Programme
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Medical Technologies Evaluation Programme Sponsor submission of evidence: Evaluation title: Sponsor: Date sections A and B submitted: Date section C submitted:
More informationThe Advancing Health Equity: Leading Care, Payment, and Systems Transformation Learning Collaborative
The Advancing Health Equity: Leading Care, Payment, and Systems Transformation Learning Collaborative Frequently Asked Questions Updated as of 4/09/19 General 1. Who do I contact for questions about the
More informationJOB DESCRIPTION. Job title: Service Delivery Specialist Location: Kampala
JOB DESCRIPTION Job title: Service Delivery Specialist Location: Kampala Department: Technical Length of contract: Fixed Role type: National Grade: 9 Travel involved: Up to 40% travel to areas of operation
More informationReview of information management practices at BreastCheck
Review of information management practices at BreastCheck March 2018 Page 1 of 78 About the The (HIQA) is an independent authority established to drive high quality and safe care for people using our health
More informationWalberswick Parish Council Job Evaluation Review of Parish Clerk Salary May 2013
1.Introduction Walberswick Parish Council Job Evaluation Review of Parish Clerk Salary May 2013 1.1The East of England Local Government Association (EELGA) was approached in March 2013 to undertake Job
More informationPublic release of clinical information in drug submissions and medical device applications
Public release of clinical information in drug submissions and medical device applications Health Products and Food Branch March 10, 2017 Health Canada is the federal department responsible for helping
More informationOklahoma Cooperative Extension Service
Oklahoma Cooperative Extension Service Performance Appraisal County Extension Educator Guide Purpose Performance Appraisal is an integral part of Extension planning, teaching, supervision, and salary administration.
More informationIndependent Patient Safety Investigation Service Expert Advisory Group Call for Evidence
Independent Patient Safety Investigation Service Expert Advisory Group Call for Evidence Overview In July 2015 the Rt. Hon Jeremy Hunt MP, Secretary of State for Health, announced the Government s intention
More informationSchool of Economics and Management LIUC University, Castellanza, Italy
Stefano Capri School of Economics and Management LIUC University, Castellanza, Italy scapri@liuc.it ISPOR Issue Panel, Dublin SESSION IV, Wednesday, 6 November 2013 What should health economists, from
More informationMeasuring Impact of Patient- and Family- Centered Care
FACT SHEET Measuring Impact of Patient- and Family- Centered Care JUNE 2014 Why Measure Impact? Taking a patient- and family-centered approach to care has consistently been shown to improve the quality,
More informationUsing Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer
Using Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer Aris Angelis and Panos Kanavos Advance HTA Conference, London, November
More informationHTAi/ WHO Collaboration Plan Template for
HTAi/ WHO Collaboration Plan Template for 2014-2016 In accordance with the terms of the Principles governing relations between WHO and NGOs, the WHO Executive Board is considering admission of HTAi (Health
More informationWORLD HEALTH ORGANIZATION. Guidelines on working with the private sector to achieve health outcomes
WORLD HEALTH ORGANIZATION EXECUTIVE BOARD 107th Session 30 November 2000 Provisional agenda item 8.3 Guidelines on working with the private sector to achieve health outcomes Report by the Secretariat 1.
More informationCompilation Engagements
IFAC Board Final Pronouncement March 2012 International Standard on Related Services ISRS 4410 (Revised), Compilation Engagements The International Auditing and Assurance Standards Board (IAASB) develops
More informationOVERCOMING BARRIERS TO EVIDENCE GENERATION FOR GENOMIC DIAGNOSTIC TESTS. Sean Tunis MD, MSc November 17, 2010
OVERCOMING BARRIERS TO EVIDENCE GENERATION FOR GENOMIC DIAGNOSTIC TESTS Sean Tunis MD, MSc November 17, 2010 EGAPP Working Group (Teutsch et al, Genet Med, 2008) Of most concern, the number and quality
More informationBETTER REGULATION IN EUROPE: AN OECD ASSESSMENT OF REGULATORY CAPACITY IN THE 15 ORIGINAL MEMBER STATES OF THE EU PROJECT GLOSSARY
EUROPEAN COMMISSION BETTER REGULATION IN EUROPE: AN OECD ASSESSMENT OF REGULATORY CAPACITY IN THE 15 ORIGINAL MEMBER STATES OF THE EU PROJECT GLOSSARY BETTER REGULATION IN EUROPE: AN OECD ASSESSMENT OF
More informationTAMD - Climate Change Indicator - Methodological Note
TAMD - Climate Change Indicator - Methodological Note Short title Type or Indicator Technical definition/ Methodological summary INDICATOR 8. AWARENESS AMONG STAKEHOLDERS Awareness of climate change issues,
More informationGuide for Terms of Reference
Centre for Research on Impact Evaluation (CRIE) Guide for Terms of Reference Template 1. Introduction and Description of the Intervention (1.1) Purpose, objectives and intended outcomes [Set out the purpose,
More informationAnnex 9. Good review practices: guidelines for national and regional regulatory authorities 1. Background
Annex 9 Good review practices: guidelines for national and regional regulatory authorities 1 Background The good review practices (GRevP) guidelines for regulatory authorities emanate from a partnership
More informationStandards for Doctoral programmes in Forensic Psychology
Standards for Doctoral programmes in Forensic Psychology Approved: May 2014 Introduction In 2012, the Partnership and Accreditation Committee (PAC) commenced a process of review in collaboration with its
More informationDRAFT FOR PUBLIC COMMENT Guidance Note for ESS10 Stakeholder Engagement and Information Disclosure
The Guidance Notes provide guidance for the Borrower on the application of the Environmental and Social Standards (ESSs), which form part of the World Bank s 2016 Environmental and Social Framework. The
More information